TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
$42.09+1.50%
Close 2026-10-30 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
Research Workspace
Put TEVA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is contracting — down about 15% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskTEVA’s case rests on innovative brands and pipeline launches, with cash backing reported profits. Its latest quarter missed, with revenue down 1% year over year. The miss tempers its strong recent performance and supportive sector backdrop. TEVA trades at 14× P/E versus a 16× peer median. Its own historical multiple is 14×, and expectations look modest versus our view. A 17% next-quarter miss probability and the latest earnings miss threaten that case. Peer multiples imply a price about 27% below where it trades. Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-30. TEVA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 13 analysts currently covering TEVA (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for TEVA in the last 4 months.
Continue this research
Compare TEVA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TEVA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put TEVA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Execute Pivot to Growth strategy with focus on innovative brands
Weltruza approval supports growth strategy and innovative brands.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $42.09
The last 12 months of price, then the range of analyst 12-month targets from today’s $42.09.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Execute Pivot to Growth strategy with focus on innovative brands
Oppenheimer's target raise indicates confidence in growth strategy.
Advances: Advance late-stage innovative pipeline and new product launches
FDA approval of Weltruza supports innovative pipeline advancement.
Advances: Advance late-stage innovative pipeline and new product launches
Pipeline rating indicates confidence in product launches.
Advances: Execute Pivot to Growth strategy with focus on innovative brands
Focus on growth aligns with management's strategy.
Advances: Execute Pivot to Growth strategy with focus on innovative brands
Growth plan traction supports overall strategy.
Advances: Advance late-stage innovative pipeline and new product launches
New data supports innovative pipeline advancement.
Advances: Advance late-stage innovative pipeline and new product launches
Post-hoc data enhances product launch potential.